MBX Biosciences (MBX) analyst forecast and price target
Analyst forecast
Consensus of 11 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Stifel | Maintained | Buy | $84.00 from $70.00 | Oct 12, 2026 |
| Guggenheim | Maintained | Buy | $150.00 from $88.00 | Oct 2, 2026 |
| JP Morgan | Maintained | Overweight | $88.00 | Aug 21, 2026 |
| Truist Securities | Maintained | Buy | $88.00 from $70.00 | Aug 10, 2026 |
| Mizuho | Maintained | Outperform | $91.00 from $57.00 | Jul 29, 2026 |
| Barclays | Maintained | Overweight | $70.00 from $66.00 | May 12, 2026 |
| Citizens | Maintained | Market Outperform | $86.00 from $76.00 | May 12, 2026 |
| Truist Securities | Maintained | Buy | $70.00 from $50.00 | May 11, 2026 |
| Barclays | Initiated Coverage | Overweight | $66.00 | Jan 28, 2026 |
| Guggenheim | Maintained | Buy | $88.00 from $77.00 | Jan 16, 2026 |
| UBS | Initiated Coverage | Buy | $60.00 | Jan 7, 2026 |
| Stifel | Maintained | Buy | $50.00 from $45.00 | Dec 19, 2025 |
| Goldman Sachs | Initiated Coverage | Sell | $18.00 | Dec 4, 2025 |
| Guggenheim | Maintained | Buy | $77.00 from $84.00 | Nov 10, 2025 |
| TD Cowen | Initiated Coverage | Buy | — | Nov 4, 2025 |
| Truist Securities | Initiated Coverage | Buy | $50.00 | Oct 15, 2025 |
| Mizuho | Maintained | Outperform | $56.00 from $38.00 | Sep 24, 2025 |
| Guggenheim | Maintained | Buy | $84.00 from $44.00 | Sep 23, 2025 |
| Oppenheimer | Maintained | Outperform | $80.00 from $38.00 | Sep 23, 2025 |
| Jefferies | Initiated Coverage | Buy | $36.00 | Aug 15, 2025 |
Frequently asked questions
What is the price target for MBX stock?
The average 12-month analyst price target for MBX Biosciences (MBX) is $100.20, with a high estimate of $150.00 and a low of $84.00, across 5 analysts.
Is MBX a buy, sell, or hold?
Analysts covering MBX Biosciences currently average a Buy rating: 11 buy, 0 hold and 0 sell, from 11 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for MBX?
The average price target of $100.20 implies 105.24% upside from the last price of $48.82.
What is the latest analyst rating on MBX?
On Oct 12, 2026, Stifel maintained MBX Biosciences at Buy with a price target of $84.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.